DUBLIN – Pieris Pharmaceuticals Inc., logged its first partnering deal in immuno-oncology, a pact worth up to CHF415 million (US$416 million) with Roche AG, involving a single undisclosed target against which the German-American biotech will deploy its anticalin scaffold technology.
DUBLIN – AB Science SA took a step closer to its first product approval, with a first positive read out of its tyrosine kinase inhibitor masitinib in a phase III trial. The Paris-based firm disclosed last week that it had reached the primary endpoint of a phase III study in severe systemic mastocytosis. It released detailed data from the trial Monday.
STRASBOURG, France – With about €1.3 billion under management, Sofinnova Partners is one of the biggest – and most active – players in European VC. It is also about to add to that number. "We're in the process of closing our eighth fund," Sara Nunez Garcia, senior associate at Paris-based Sofinnova, told delegates during a panel on the differing approaches to risk assessment that VCs take in North America, Europe and Asia. It will, like its predecessors, be in the €250 million to €300 million range.
DUBLIN – Pfizer Inc. (New York) is swapping its New York home for an Irish domicile by combining with Allergan plc (Dublin) in an all-share deal, which values the latter firm at $160 billion and which will cut Pfizer's tax rate from its reported rate of 25.5 percent in 2014 to 17 percent to 18 percent for the combined company.
DUBLIN – Pfizer Inc. is swapping its New York home for an Irish domicile by combining with Allergan plc in an all-share deal, which values the latter firm at $160 billion and which will cut Pfizer's tax rate from its reported rate of 25.5 percent in 2014 to 17 percent to 18 percent for the combined company.
DUBLIN – Obseva SA closed a $60 million series B round to progress its pipeline of drugs focused on women's reproductive health and to give it enough firepower to add further projects to its portfolio.
DUBLIN – Pfizer Inc. and Les Laboratoires Servier SAS both moved quickly to secure an interest in Cellectis SA's UCART19 allogeneic CAR T-cell therapy, which recently attained clinical proof of concept, in spectacular fashion, in acute lymphoblastic leukemia (ALL).
DUBLIN – Swiss orphan drug developer AB2 Bio Ltd. has obtained dramatic clinical proof of concept for its recombinant interleukin-18-binding protein (IL-18BP) therapy (tadekinig alfa), in an exceptional case involving an infant girl at risk of death from severe systemic inflammation.
DUBLIN – Pierre Fabre SA is paying Array Biopharma Inc. $30 million up front plus up to $425 million more in milestones for European, Asian and Latin American rights to its phase III Mek inhibitor binimetinib and its phase III BRAF inhibitor encorafenib, thereby cleaning up the fallout from Novartis AG's purchase of Glaxosmithkline plc's oncology business.
